Novel spirooxindole-triazole derivatives: unveiling [3+2] cycloaddition reactivity through molecular electron density theory and investigating their potential cytotoxicity against HepG2 and MDA-MB-231 cell lines.

Autor: Shawish, Ihab¹ (AUTHOR) ishawish@psu.edu.sa, Al Ayoubi, Samha¹ (AUTHOR), El-Faham, Ayman² (AUTHOR) ishawish@psu.edu.sa, Aldalbahi, Ali³ (AUTHOR), El-Senduny, Fardous F.^4,5 (AUTHOR), Badria, Farid A.⁶ (AUTHOR), Ríos-Gutiérrez, Mar⁷ (AUTHOR), Hammud, Hassan H.⁸ (AUTHOR), Ashraf, Sajda⁹ (AUTHOR), Ul-Haq, Zaheer⁹ (AUTHOR), Barakat, Assem³ (AUTHOR)

Publikováno v: Frontiers in Chemistry. 2024, p1-20. 20p.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

Autor: Gluck WL; Prisma Health - Upstate, Institute for Translational Oncology Research, 900 W. Faris Rd., 3rd Floor, Greenville, SC, 29605, USA. larry.gluck@prismahealth.org., Gounder MM; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Frank R; Whittingham Cancer Center, Norwalk, CT, USA., Eskens F; Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Blay JY; Department of Medicine, Centre Léon Bérard, Lyon, France., Cassier PA; Department of Medicine, Centre Léon Bérard, Lyon, France., Soria JC; Department of Medicine, The Institute Gustave-Roussy, Paris, France.; Université Paris Sud, Orsay, France., Chawla S; Sarcoma Oncology Center, Cancer Center of Southern California, Santa Monica, CA, USA., de Weger V; Department of Internal Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wagner AJ; Center for Sarcoma and Bone Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Siegel D; Multiple Myeloma Division, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ, USA., De Vos F; Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Rasmussen E; Oncology Early Development, Amgen Inc., Thousand Oaks, CA, USA., Henary HA; Oncology Early Development, Amgen Inc., Thousand Oaks, CA, USA.

Publikováno v: Investigational new drugs [Invest New Drugs] 2020 Jun; Vol. 38 (3), pp. 831-843. Date of Electronic Publication: 2019 Jul 29.

Scapula alata as presenting symptom of Fanconi anemia: A case for serendipity.

Autor: van Adrichem R; Department of Paediatrics and Neonatology Dijklander Hospital Hoorn The Netherlands., de Weger V; Department of Paediatrics and Neonatology Dijklander Hospital Hoorn The Netherlands., Broere D; Department of Neurology Dijklander Hospital Hoorn The Netherlands., van Herrewegen F; Department of Paediatrics and Neonatology Dijklander Hospital Hoorn The Netherlands., Amaya J; Department of Orthopaedics Dijklander Hospital Hoorn The Netherlands., Ten Tusscher GW; Department of Paediatrics and Neonatology Dijklander Hospital Hoorn The Netherlands.

Publikováno v: Clinical case reports [Clin Case Rep] 2019 Jul 23; Vol. 7 (9), pp. 1660-1662. Date of Electronic Publication: 2019 Jul 23 (Print Publication: 2019).

Targeted Therapy in Mesotheliomas: Uphill All the Way.

Autor: Bertoli, Elisa¹ (AUTHOR) elisa.bertoli@cro.it, De Carlo, Elisa¹ (AUTHOR) elisa.decarlo@cro.it, Bortolot, Martina^1,2 (AUTHOR) martina.bortolot@cro.it, Stanzione, Brigida¹ (AUTHOR) brigida.stanzione@cro.it, Del Conte, Alessandro¹ (AUTHOR) alessandro.delconte@cro.it, Spina, Michele¹ (AUTHOR) mspina@cro.it, Bearz, Alessandra¹ (AUTHOR) abearz@cro.it

Publikováno v: Cancers. Jun2024, Vol. 16 Issue 11, p1971. 25p.

303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors

Autor: De Weger, V., Varga, A., De Jonge, M., Langenberg, M., Mergui-Roelvink, M., Massard, C., Van der Vlist, A., Devriese, L., Goodstal, S., Zheng, W., Tuffal, G., Semiond, D., Macé, S., Watters, J., Demers, B., Schellens, J., Deutsch, E.

Publikováno v: In European Journal of Cancer September 2015 51 Supplement 3:S55-S55